PMID- 24916302
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20220330
IS  - 1471-499X (Electronic)
IS  - 1471-4914 (Linking)
VI  - 20
IP  - 8
DP  - 2014 Aug
TI  - Caloric restriction and cancer: molecular mechanisms and clinical implications.
PG  - 419-27
LID - S1471-4914(14)00080-X [pii]
LID - 10.1016/j.molmed.2014.05.001 [doi]
AB  - Caloric restriction (CR) is currently the most robust environmental intervention 
      known to increase healthy life and prolong lifespan in several models, from yeast 
      to mice. Although the protective effect of CR on the incidence of cancer is well 
      established, its impact on tumor cell responses to chemotherapeutic treatment is 
      currently being investigated. Interestingly, the molecular mechanisms required to 
      extend lifespan upon reduced food intake are being evaluated, and these 
      mechanisms may offer new opportunities for therapeutic intervention. In addition, 
      new findings suggest a beneficial effect of CR in enhancing the efficiency of 
      tumor cell killing by chemotherapeutic drugs and inducing an anticancer immune 
      response.
CI  - Copyright (c) 2014 Elsevier Ltd. All rights reserved.
FAU - Meynet, Ophelie
AU  - Meynet O
AD  - Inserm, U1065, Centre Mediterraneen de Medecine Moleculaire (C3M), Equipe 
      "Controle Metabolique des Morts Cellulaires", 06204 Cedex 3, Nice, France; 
      Universite de Nice Sophia-Antipolis, Faculte de Medecine, 06100, Nice, France.
FAU - Ricci, Jean-Ehrland
AU  - Ricci JE
AD  - Inserm, U1065, Centre Mediterraneen de Medecine Moleculaire (C3M), Equipe 
      "Controle Metabolique des Morts Cellulaires", 06204 Cedex 3, Nice, France; 
      Universite de Nice Sophia-Antipolis, Faculte de Medecine, 06100, Nice, France; 
      Centre Hospitalier Universitaire de Nice, Departement d'Anesthesie Reanimation, 
      06204 Cedex 3, Nice, France. Electronic address: ricci@unice.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140608
PL  - England
TA  - Trends Mol Med
JT  - Trends in molecular medicine
JID - 100966035
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
SB  - IM
CIN - Trends Mol Med. 2014 Sep;20(9):471-2. PMID: 25066728
MH  - AMP-Activated Protein Kinases/metabolism
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - *Caloric Restriction/methods
MH  - Combined Modality Therapy/methods
MH  - Humans
MH  - Neoplasms/*diet therapy/drug therapy/immunology/*metabolism
MH  - TOR Serine-Threonine Kinases/metabolism
OTO - NOTNLM
OT  - AMPK
OT  - caloric restriction
OT  - cancer
OT  - chemotherapy
OT  - immune response
OT  - mTOR
EDAT- 2014/06/12 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/06/12 06:00
PHST- 2014/01/28 00:00 [received]
PHST- 2014/04/30 00:00 [revised]
PHST- 2014/05/07 00:00 [accepted]
PHST- 2014/06/12 06:00 [entrez]
PHST- 2014/06/12 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - S1471-4914(14)00080-X [pii]
AID - 10.1016/j.molmed.2014.05.001 [doi]
PST - ppublish
SO  - Trends Mol Med. 2014 Aug;20(8):419-27. doi: 10.1016/j.molmed.2014.05.001. Epub 
      2014 Jun 8.